Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15089438 | 1.00 | TDP1 (0.50) | TDP1LMNAALDH1A1TSHRTHRB | |
| SCHEMBL16556824 | 1.00 | TDP1 (0.50) | TDP1LMNAALDH1A1TSHRTHRB | |
| SCHEMBL283526 | 0.94 | — | — | |
| SCHEMBL19450283 | 0.87 | TSHR (0.44) | TDP1LMNAALDH1A1TSHR | |
| SCHEMBL19449972 | 0.87 | TSHR (0.44) | TDP1LMNAALDH1A1TSHR | |
| SCHEMBL19450212 | 0.87 | TSHR (0.44) | TDP1LMNAALDH1A1TSHR | |
| SCHEMBL12915076 | 0.87 | TSHR (0.44) | TDP1LMNAALDH1A1TSHR | |
| SCHEMBL14969788 | 0.87 | TSHR (0.44) | TDP1LMNAALDH1A1TSHR | |
| SCHEMBL12560763 | 0.87 | TSHR (0.44) | TDP1LMNAALDH1A1TSHR | |
| SCHEMBL1535121 | 0.84 | TSHR (0.47) | TDP1LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10218736-A | — | — | None | — | — | JP | disclosed |
| US-8558038-B2 | Epoxidation of glycerol and derivatives therefrom | AEL MINING SERVICES LIMITED (ZA) | 2013-10-15 | — | — | US | disclosed |
| US-8558038-B2 | Epoxidation of glycerol and derivatives therefrom | AEL MINING SERVICES LIMITED (ZA) | 2013-10-15 | — | — | US | disclosed |
| US-20130090497-A1 | EPOXIDATION OF GLYCEROL AND DERIVATIVES THEREFROM | AEL MINING SERVICES LIMITED (ZA) | 2013-04-11 | — | — | US | disclosed |
| US-20130090497-A1 | EPOXIDATION OF GLYCEROL AND DERIVATIVES THEREFROM | AEL MINING SERVICES LIMITED (ZA) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003519-A1 | EPOXIDATION OF GLYCEROL AND DERIVATIVES THEREFROM | AEL MINING SERVICES LIMITED (ZA) | 2012-01-05 | — | — | WO | disclosed |
| US-20080102121-A1 | COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2008-05-01 | — | — | US | disclosed |
| EP-1562954-B1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20040137019-A1 | Cosmetic w/o/w emulsion preparation | SHISEIDO COMPANY, LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1369101-A1 | COSMETIC W/O/W EMULSION PREPARATION | SHISEIDO COMPANY LIMITED (JP) | 2003-12-10 | — | — | EP | disclosed |
| JP-H10218736-A | HAIR GROWER | TAISHO PHARMACEUT CO LTD | 1998-08-18 | — | — | JP | disclosed |
| US-5571812-A | TREATMENT OF INFECTIONS OF GRAMNEGATIVE AND GRAMPOSITIVE BACTERIA | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-05 | — | — | US | disclosed |
| US-4913900-A | AQUEOUS SOLUTION OF THIOGLYCOLATE AND DITHIODIGLYCOLATE SALTS, POLYHYDRIC MOISTURIZER, ALKALI; SUITABLE FOR DAMAGED HAIR | HELENE CURTIS, INC. (US) | 1990-04-03 | — | — | US | disclosed |
| EP-0344653-A2 | Conditioning perm wave composition and method | Helene Curtis Industries, Inc. (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080102121-A1 | COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE | OPRM1, MCHR1, CYP3A43 | TDP1 2282/4885LMNA 3414/4885ALDH1A1 298/4885 |
| US-20130090497-A1 | EPOXIDATION OF GLYCEROL AND DERIVATIVES THEREFROM | GK, UGCG, GYPA | TDP1 3434/4885LMNA 2360/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.